H.C. Wainwright Keeps Buy on Madrigal Pharmaceuticals (MDGL) on Strong Rezdiffra Uptake and F2/F3 MASH Patient Data

Core Insights - Madrigal Pharmaceuticals Inc. is identified as a high short interest stock with a price target increase from H.C. Wainwright to $620, reflecting confidence in the company's product Rezdiffra and its market potential [1] Financial Performance - In Q3 2025, Madrigal reported net sales of $287.3 million, a 35% sequential increase, with over 29,500 patients on Rezdiffra therapy, up from over 23,000 in the previous quarter [2] Market Access and Growth - The company has achieved broad first-line access for Rezdiffra with no step edit requirements in payer contracting for 2026, indicating strong market positioning [3] - Adherence rates for Rezdiffra are stable, ranging from 60% to 70%, comparable to other well-tolerated oral medications [3] - Madrigal has successfully launched Rezdiffra in Germany following European approval, although the impact on 2026 growth is expected to be modest, with the US market driving most growth [3]